6 results  1 of 1 

1 Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Hyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim
Cancer Res Treat.2022;54(2):469-477.   Published online 2021 June 23     DOI: http://dx.doi.org/10.4143/crt.2021.205
      
2 Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
Mijin Kim, Jee Hee Yoon, Jonghwa Ahn, Min Ji Jeon, Hee Kyung Kim, Dong Jun Lim, Ho-Cheol Kang, In Joo Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim
Endocrinol Metab.2020;35(3):587-594.   Published online 2020 September 22     DOI: http://dx.doi.org/10.3803/EnM.2020.687
      
3 Skin-Related Toxicity of Tyrosine Kinase Inhibitor in Thyroid Cancer
Dong-Jun Lim
Int J Thyroidol.2018;11(2):82-87.   Published online 2018 November 30     DOI: http://dx.doi.org/10.11106/ijt.2018.11.2.82
      
4 The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer
June-Koo Lee, Dong-Wan Kim, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Young-Joo Kim, Dae Seog Heo
Cancer Res Treat.2015;47(2):182-188.   Published online 2014 September 12     DOI: http://dx.doi.org/10.4143/crt.2013.227
      
5 Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors
Sei-Hoon Yang
Tuberc Respir Dis.2013;75(5):188-198.   Published online 2013 November 29     DOI: http://dx.doi.org/10.4046/trd.2013.75.5.188
      
6 Development of Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia
Hawk Kim
Hanyang Med Rev.2012;32(2):103-111.   Published online 2012 May 25     DOI: http://dx.doi.org/10.7599/hmr.2012.32.2.103
      

 1 of 1